CAS: 60-51-5; Dimethoate

上下游产品

CAS号74-89-5 氨基甲烷 | CAS号96-30-0 2-氯-N-甲基乙酰胺 | CAS号16001-68-6 O,O-DIMETHYLPHO... | CAS号34680-81-4 2-溴-N-甲基乙酰胺 | CAS号757-86-8 硫磷酯 | CAS号1112-38-5 O,O-二甲基氢硫代磷酸酯 | CAS号20938-74-3 n-甲基-硫代乙酰胺 | CAS号3268-87-9 1,2,3,4,6,7,8,9... | CAS号1113-02-6 氧化乐果 | CAS号63124-33-4 2-dimethoxyphos...

甲胺,Alkaline Earth Salt Of/the/ Methylsulfuric Acid置于2-己酮体系中,化学反应生成 乐果
参考文献:Schrader,G.,Die Entwicklung Neuer Insektizider Phosphorsaeure-Ester,3. Aufl. S. 117,122
标题:Schrader,G.,Die Entwicklung Neuer Insektizider Phosphorsaeure-Ester,3. Aufl. S. 117,122

专利信息

专利号:US-9446995-B2
优先权日:2012-05-21
标 题:Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
发明人：CHONG HYUN-SOON
权利人:CHONG HYUN-SOON; ILLINOIS INST OF TECH
摘要:Stereoselective and regioselective synthesis of compounds via nucleophilic ring opening reactions of aziridinium ions for use in stereoselective and regioselective synthesis of therapeutic and diagnostic compounds.

专利号:US-10189803-B2
优先权日:2008-02-22
标题 :Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
发明人：CHONG HYUN-SOON
权利人:CHONG HYUN SOON; ILLINOIS INSTITUTE OF TECH
摘要:Stereoselective and regioselective synthesis of compounds via nucleophilic ring opening reactions of aziridinium ions for use in stereoselective and regioselective synthesis of therapeutic and diagnostic compounds.

专利号:US-8043816-B2
优先权日:1999-07-02
标题 :Compositions and methods for temperature-dependent nucleic acid synthesis
发明人：ASTATKE MEKBIB; CHATTERJEE DEB K; GERARD GARY F
权利人:LIFE TECHNOLOGIES CORP
摘要:The present invention relates to nucleic acid inhibitors, compositions and method for enhancing synthesis of nucleic acid molecules. In a preferred aspect, the invention relates to inhibition or control of nucleic acid synthesis, sequencing or amplification. Specifically, the present invention discloses nucleic acids having affinity for polypeptides with polymerase activity for use in such synthesis, amplification or sequencing reactions. The nucleic acid inhibitors are capable of inhibiting nonspecific nucleic acid synthesis under certain conditions (e.g., at ambient temperatures). Thus, in a preferred aspect, the invention relates to “hot start†synthesis of nucleic acid molecules. Accordingly, the invention prevents, reduces or substantially reduces nonspecific nucleic acid synthesis. The invention also relates to kits for synthesizing, amplifying, reverse transcribing or sequencing nucleic acid molecules comprising one or more of the nucleic acid inhibitors or compositions of the invention. The invention also relates to using the inhibitors of the invention to prevent viral replication or treat viral infections in a subject. Thus, the invention relates to therapeutic methods and pharmaceutical compositions using the inhibitors of the invention. The invention thus may be used for in vivo and in vitro inhibition of nucleic acid synthesis and/or inhibition of polymerase acivity.

专利号:EP-1196559-B1
优先权日:1999-07-02
标 题 :Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
发明人：ASTATKE MEKBIB; CHATTERJEE DEB; GERARD GARY
权利人:INVITROGEN CORP
摘要:The present invention relates to nucleic acid inhibitors, compositions and method for enhancing synthesis of nucleic acid molecules. In a preferred aspect, the invention relates to inhibition or control of nucleic acid synthesis, sequencing or amplification. Specifically, the present invention discloses nucleic acids having affinity for polypeptides with polymerase activity for use in such synthesis, amplification or sequencing reactions. The nucleic acid inhibitors are capable of inhibiting nonspecific nucleic acid synthesis under certain conditions (e.g., at ambient temperatures). Thus, in a preferred aspect, the invention relates to 'hot start' synthesis of nucleic acid molecules. Accordingly, the invention prevents, reduces or substantially reduces nonspecific nucleic acid synthesis. The invention also relates to kits for synthesizing, amplifying, reverse transcribing or sequencing nucleic acid molecules comprising one or more of the nucleic acid inhibitors or compositions of the invention. The invention also relates to using the inhibitors of the invention to prevent viral replication or treat viral infections in a subject. Thus, the invention relates to therapeutic methods and pharmaceutical compositions using the inhibitors of the invention. The invention thus may be used for in vivo and in vitro inhibition of nucleic acid synthesis and /or inhibition of polymerase acitivity.

专利号:WO-2009049476-A1
优先权日:2007-09-20
标题 :Process for the manufacture of (+)-biotin
发明人：CHEN FEN-ER; DAI HUI-FANG; HUANG JIAN; XIONG FEI; JING SHU-PING
权利人:DSM IP ASSETS BV; UNIV FUDAN; CHEN FEN-ER; DAI HUI-FANG; HUANG JIAN; XIONG FEI; JING SHU-PING
摘要:Disclosed are processes for preparing synthetic biotin intermediates and a process for preparing biotin using said intermediates. In particular, disclosed is a process for the stereoselective total synthesis of the natural product (+)-biotin of formula (I).

专利号:WO-2004087679-A1
优先权日:2003-04-01
标 题 :2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
发明人：OBRECHT DANIEL; ERMERT PHILIPP; LUTHER ANATOL; EBERLE MARTIN; BACHMANN FELIX
权利人:APONETICS AG; OBRECHT DANIEL; ERMERT PHILIPP; LUTHER ANATOL; EBERLE MARTIN; BACHMANN FELIX
摘要:The invention relates to substituted pyrimidines of formula (I) wherein V represents a bond or CR6R7, W represents a bond, NR8 or oxygen, X represents sulfur, or nitrogen substituted by hydrogen or R5, Y represents -CH2-, -CH2CH2-, -CO- or -CS-, R1 represents unsubstituted or substituted aryl or heteroaryl, and the substituents R2, R3, R4, R5, R6, R7 and R8 have the meanings given in the specification. These compounds are selectively inducing apoptosis in cancer cells and can be used for the treatment of neoplastic and autoimmune diseases. The invention relates also to methods of synthesis of such compounds, to their use as medicaments, to pharmaceutical compositions containing same, and to methods of treatment of neoplastic and autoimmune diseases using such compounds of formula (I) or of pharmaceutical compositions containing same.